SGC 20th Anniversary Symposium

Workshop Edit tabs

Details

The Structural Genomics Consortium in Toronto (SGC-Toronto) is holding a 20th anniversary symposium on Wednesday and Thursday, March 8 and 9, 2023 at the Chelsea Hotel (Mountbatten Salon), 33 Gerrard St W, Toronto, ON, just steps from Dundas Square.

The 20th Anniversary Symposium will be a celebration of two decades of collaborative open science: past, present and future. Co-Hosted in partnership with Ontario Genomics, the University of Toronto’s Temerty Faculty of Medicine and Emerging & Pandemic Infections Consortium (EPIC), Ontario Institute for Cancer Research (OICR) and Princess Margaret Cancer Centre (PM CC).

Keynote

Dafydd Owen, Pfizer, The Discovery of Paxlovid

Details

Day 1: Oral Presentations, Poster Session & Networking Reception – Wednesday, March 8, 12 pm-6 pm, Mountbatten Salon of the Chelsea Hotel Toronto.
Day 2: Oral Presentations – Thursday, March 9, 9 am-4 pm
Abstracts: Abstracts: We invite abstracts for the Poster Session on Day 1. The best abstracts will be invited for a poster presentation and a few will be selected for a short talk.
Abstracts should be no more than 1 page (including figures) and submitted to thesgc.toronto@gmail.com by Friday, February 24, 2023, 12 PM EST.

Contact

For additional information on the SGC 20th Anniversary Symposium, please contact Rebecca Clare at rebecca.clare@utoronto.ca.

Programme

Please download final agenda here

Please download speakers' bio here

Preliminary Program Day 1

March 8. [12 pm - 6 pm]
Welcome:	Cheryl Arrowsmith
12:00-12:10 pm	Chief Scientist, SGC-Toronto, University of Toronto, Princess Margaret Cancer Centre
Session 1:	Tackling emerging infectious diseases Hosted by University of Toronto’s Emerging and Pandemic Infections Consortium (EPIC), Chaired by Natasha Christie-Holmes, Director, Strategy & Partnerships
12:10-12:45 pm	The Discovery of Paxlovid	Dafydd Owen, Pfizer
12:45-1:10 pm	Identification of CSNK2 as a host kinase target for inhibition of coronavirus replication	Tim Willson, SGC-UNC, U of North Carolina at Chapel Hill
1:10-1:35 pm	How SARS-CoV-2 changed research in Canada: a tale of CANCOV, RECLAIM and Long COVID	Angela Cheung, University Health Network, Sinai Health, University of Toronto
1:35-1:50 pm	Abstract talk: A Target Engagement Assay to Assess Uptake, Potency, and Retention of Antibiotics in Living Bacteria	Rebeka Fanti, SGC-Toronto, Department of Molecular Genetics, University of Toronto
1:50 - 2:20 pm	Coffee Break
Session 2:	Chemical Probes, a gateway to new medicines Hosted by the Ontario Institute for Cancer Research (OICR), Chaired by Laszlo Radvanyi, President and Scientific Director
2:20-2:45pm	Discovery and development of WDR inhibitors	Rima Al-awar, OICR
2:45-3:10pm	Targeting the human kinome	Stefan Knapp, SGC-Frankfurt, Goethe University Frankfurt
3:10-3:45pm	Development of high-affinity structure- validated binders of the Huntington’s disease protein	Rachel Harding, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
3:45-4:00 pm	Abstract talk: Development and preliminary characterization of a uniquely selective, first-class, publicly available chemical probe for the understudied citron kinase	Jesse. Coker, Center for Therapeutics Discovery, Lerner Research Institute, Cleveland Clinic
4:00 - 6:00 pm	Poster Session and Networking Reception

Preliminary Program Day 2

March 9. [9 am - 4 pm]
Session 3:	Probing the human (epi)genome for therapeutic opportunities Hosted by Princess Margaret Cancer Centre, Chaired by Brad Wouters, Executive VP Science and Research, University Health Network
9:00-9:25 am	Regulation of Endogenous Retroelements as an Emerging Vulnerability and Therapeutic Opportunity in Cancer Treatment and Interception	Daniel De Carvalho, Princess Margaret Cancer Centre
9:25-9:50 am	Targeting epigenetic regulation in clear cell renal cell carcinoma reveals PRMT1 as a novel target	Joe Walton, Princess Margaret Cancer Centre
9:50-10:05 am	Abstract talk: Investigation of the role of the epigenetic regulator, protein arginine methyltransferase 3 (PRMT3), in cancer stem cell populations	Ravinder K Bahia,, Department of Cell Biology and Anatomy,, University of Calgary
10:05-10:20 am	Abstract talk: Suppressing cancer stem cell functions in colon tumors by antagonizing dopamine transporter	Yannick D. Benoit, Department of Cellular and Molecular Medicine, University of Ottawa
10:20 - 10:50 am	Coffee Break
Session 4:	New tools for targeted protein degradation Chaired by Sujata Sharma, Director, Structural & Protein Sciences, Janssen R&D
10:50-11:15 am	Interrogation of the GID4 interactome with PFI-7	Dominic Owens, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
11:15-11:40 am	A novel E3 handle for degradation of NSD2	David Nie, Princess Margaret Cancer Centre, SGC-Toronto
11:40-11:55 am	Abstract talk: DCAF12: a new addition to the repertoire of ubiquitin ligases for Targeted Protein Degradation	Germanna Righetto, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
11:55 am -12:10 pm	Abstract talk: PROTAC Virtual Screening Benchmark	Evianne Rovers, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
12:10 - 13:10 pm	Lunch Break
Session 5:	Initiatives to accelerate drug discovery and enhance data reproducibility Chaired by Anke Mueller-Fahrnow, Chair of the Board of SGC
1:10-1:35 pm	The Chemical Probes Portal, a free, public online resource of expert reviews and evaluations of chemical probes	Susanne Mueller-Knapp, SGC-Frankfurt, Goethe University Frankfurt
1:35-1:50 pm	CACHE: setting the stage for a breakthrough in computational hit finding	Matthieu Schapira, SGC-Toronto Department of Pharmacology & Toxicology, University of Toronto
1:50-2:15 pm	YCharOS: Antibody characterization through open science	Peter McPherson, SGC-Neuro, McGill University & YCharOS
2:15-2:30 pm	Abstract talk: Scalable Generation of Predictive Binding Models Based on DEL Screening Data	Matthew Clark, X-Chem Inc.
2:30 - 3:00 pm	Coffee Break
Session 6:	Looking toward the Future: Industry partnerships to support drug discovery Hosted by Ontario Genomics, Chaired by Bettina Hamelin, President and CEO
3:00-3:25 pm	Target 2035: WDR proteins as a technology test-bed for illuminating the dark proteome	Levon Halabelian, SGC-Toronto, Department of Pharmacology & Toxicology, University of Toronto
3:25-3:50 pm	SGC-Promega collaborations: Co-developing novel reagents for target engagement in cells	Matt Robers, Promega
3:50-4:00 pm	Looking to the future: SGC and Target 2035	Aled Edwards, SGC CEO, Department of Molecular Genetics, University of Toronto